Skip to content

PHARMAXUS

Active Private limited companyfounded 2018active for 8 yearsBeemdstraat 2, 2240 ZandhovenKBO/BCE: BE 0694.693.808

Lifetime

7 annual accounts with figures on one time axis
peak of €19,190 in 2025
€19,190▲ 247%
lowest -€19,657 in 2021
€13,337▲ 214%
peak of €6,551 in 2025
€6,551▲ €13,337
€18,635▼ 3.8%
Board1 name since 2018
1 director
Documentsfilings and deeds
07-07-202624 days before the deadline
2025micro format
Gross margin from €5,529 to €19,190Result from €4,246 to €13,337Equity from -€6,786 to €6,551Cash from €1,676 to €974

Key points

from the 2025 annual accounts

Debts

€18,635 74% of the balance sheet
Suppliers 10%Taxes and wages 61%Other 29%

Liquidity

1.35 was 0.64 in 2024

Short-term debts fell from €19,372 to €18,635.

Filings

7 annual accounts since 2019
AprilJune31 JulyOctober202020222024

The last five annual accounts were filed 8 to 27 days before the end of the period.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 6,715 companies had the same profile as PHARMAXUS has now. Each dot stands for 17 companies, two years later.

95.8%
were still trading
2.2%
stopped another way
1.8%
went bankrupt
  • Micro
  • 5 to 10 years old
  • solvency 10 to 30%
  • a profit of 5% of the balance sheet or more

Another 0.1% stopped without a precise date, possibly only after those two years.

Test of the method

The method was tested on the 497,965 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 6,715 companies, not a prediction for PHARMAXUS. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director
  • 100 sharesdeed of 16-04-2018
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0694693808
reappointed as director General meeting of 05-12-2023 · Gazette deed
Registered office moved from Broechem to Viersel The registered office moved from Gustaaf Peetersstraat 59, 2520 Broechem to Beemdstraat 2, 2240 Viersel · Board meeting of 01-04-2021 · Gazette deed
Registered office moved from Deurne to Broechem The registered office moved from Herentalsebaan 67 bus 1 2100 Deurne to Gustaaf Peetersstraat 59 2520 Broechem · General meeting of 06-12-2018 · Gazette deed
All 18 events

Comparable companies

same main activity, similar in size and age
Company
PHARMAXUS Zandhoven €25,186 €19,190 26.0% -
JL PHARMA Stoumont €22,608 €15,096 47.5% -
Farmaco Ranst €17,325 €22,129 5.8% -
DEL PHARMA Mons €36,943 €19,174 44.1% -
LORENA BOULANGER PHARMA Chapelle-lez-Herlaimont €32,165 €14,597 80.6% -
Apotheker Silke Christiaens Lennik €37,111 €14,322 0.0% -
VanbaelenApo Bruges €39,958 €19,569 46.5% -

These companies have the same main activity as PHARMAXUS: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €17,300 and €40,000, founded between 2014 and 2020.

Official details

Source: KBO
Status
Active since 12-04-2018Normal situation
Activity
Retail sale of pharmaceutical productsNACE 47730and 2 others
Establishment unit
2.275.649.4942240 Zandhoven, registered on 12-04-2018
Financial year end
31 December
Peppol
Reachable since 02-11-2025
Company details

Annual accounts 2025

≈ €200,000estimated
€25,186▲ 100%
Filing
Filed on 07-07-2026, 24 days before the end of the filing period
Financials

Insights on PHARMAXUS

PHARMAXUS files the micro format. That format states no turnover. The gross margin rose from €6,555 in 2019 to €19,190 in 2025.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about PHARMAXUS

What is the company number of PHARMAXUS?
The company number of PHARMAXUS is 0694.693.808. The VAT number is the same number with BE in front: BE 0694.693.808.
Where is PHARMAXUS based?
The registered office is at Beemdstraat 2, 2240 Zandhoven.Company details
What does PHARMAXUS do?
According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
What is the legal form of PHARMAXUS?
PHARMAXUS is a private limited company (BV).
When was PHARMAXUS founded?
PHARMAXUS was founded on 12-04-2018.
Is PHARMAXUS still active?
Yes, PHARMAXUS is an active enterprise in the KBO register.
What is the turnover of PHARMAXUS?
The turnover in financial year 2025 is ≈ €200,000. This figure is estimated from the gross margin of €19,190 and 139 comparable companies (NACE 477). It probably lies between €74,000 and €430,000. It is a rough estimate.Financials
Is PHARMAXUS profitable?
In financial year 2025, PHARMAXUS made a profit of €13,337.
Where can I find the annual accounts of PHARMAXUS?
PHARMAXUS filed 7 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of PHARMAXUS due?
PHARMAXUS must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.